natgillin/translations-raw huggingface dataset:
Humira is used to treat enthesitis-related arthritis in patients from 6 years of age.
Humira je namijenjena liječenju artritisa povezanog s entezitisom u bolesnika od navršenih 6 godina.
Humira is used to treat hidradenitis suppurativa in adults.
Humira se koristi za liječenje gnojnog hidradenitisa u odraslih.
Humira is used to treat moderate to severe Crohn’s disease in adults and moderate to severe Crohn’s disease in children and adolescents from 6 years of age
Humira je namijenjena liječenju umjerene do teške Crohnove bolesti u odraslih i umjerene do teške Crohnove bolesti u djece i adolescenata u dobi od navršenih 6 godina.
Humira is used to treat moderate to severe hidradenitis suppurativa in adults.
Humira se koristi za liječenje umjerenog do teškog oblika gnojnog hidradenitisa u odraslih.
Humira is used to treat moderate to severe ulcerative colitis in adults.
Humira je namijenjena liječenju umjerenog do teškog oblika ulceroznog kolitisa u odraslih.
Humira is used to treat polyarticular juvenile idiopathic arthritis in patients from 2 years of age.
Humira je namijenjena liječenju poliartikularnog juvenilnog idiopatskog artritisa u bolesnika od navršene 2 godine.
Humira may have a minor influence on the ability to drive and use machines.
Humira može imati mali utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
Humira may have a minor influence on your ability to drive, cycle or use machines.
Humira može imati manji utjecaj na sposobnost upravljanja vozilima, biciklom i strojevima.
Humira may have a small effect on your ability to drive, cycle or use machines.
Humira može imati manji utjecaj na sposobnost upravljanja vozilima, biciklom i strojevima.
Humira must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (an inability of the heart to pump enough blood around the body).
Humira se ne smije koristiti kod bolesnika s aktivnom tuberkulozom, drugim teškim infekcijama ili umjerenim do teškim zatajenjem srca (nesposobnošću srca da pumpa dovoljne količine krvi u tijelu).
Humira n=274 (95% confidence interval)
Humira n=274 (95% interval pouzdanosti)
Humira Pre-filled Pen
Humira napunjena brizgalica
Humira should be used with caution in patients with mild heart failure (NYHA class I/II).
Zato se bolesnicima s blagim zatajenjem srca (NYHA razred I/II) Humira mora davati oprezno.
Humira treated patients demonstrated statistically significant improvement in physical function as assessed by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week 24.
Nakon 24 tjedna u bolesnika liječenih lijekom Humira je u odnosu na bolesnike liječene placebom zabilježeno statistički značajno poboljšanje fizičke funkcije, koja se ocjenjivala uz pomoć upitnika HAQ i kratke zdravstvene ankete SF 36.
Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditons for which Humira is indicated.
Liječenje lijekom Humira moraju započeti i nadzirati liječnici specijalisti s iskustvom u dijagnosticiranju i liječenju stanja za koja je Humira indicirana.
Humira was evaluated in over 3000 patients in all rheumatoid arthritis clinical trials.
Djelovanje lijeka Humira ispitivano je u više od 3000 bolesnika u svim kliničkim ispitivanjima reumatoidnog artritisa (RA).
Humira was numerically favoured for the majority of subscores with statistically significant mean differences for general vision, ocular pain, near vision, mental health, and total score in Study UV I, and for general vision and mental health in Study UV II.
Većina podrezultata brojčano je išla u prilog lijeku Humira, a srednje vrijednosti razlike bile su statistički značajne za opći vid, bol u oku, vid na blizinu, mentalno zdravlje i ukupan rezultat u ispitivanju UV I te za opći vid i mentalno zdravlje u ispitivanju UV II.
Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or more.
Humira je ispitivana u 9506 bolesnika u pivotalnim kontroliranim i otvorenim ispitivanjima tijekom razdoblja do 60 mjeseci ili dulje.
Humira with food and drink
Humira s hranom i pićem
Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA I and II.
Djelovanje lijeka Humira u dozi od 40 mg svaka dva tjedna ispitivano je u bolesnika s umjereno teškim do teškim aktivnim psorijatičnim artritisom u dva placebom kontrolirana ispitivanja, ispitivanja PsA I i II.
Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II.
Djelovanje lijeka Humira u dozi od 40 mg svaka dva tjedna ispitivano je u bolesnika s umjereno teškim do teškim aktivnim psorijatičnim artritisom u dva placebom kontrolirana ispitivanja, ispitivanja PsA I i II.
Humira, when used as directed, has been shown in clinical trials to be effective at reducing important symptoms of each of the conditions for which it has been recommended.
Lijek Humira, kada se koristio prema naputku, u kliničkim se ispitivanjima pokazao učinkovitim u smanjenju važnih simptoma svakog stanja za čije se liječenje preporučuje.
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 4).
Radiološki nalazi u bolesnika liječenih kombinacijom lijeka Humira i metotreksata pokazali su znatno sporiju progresiju strukturnih oštećenja zglobova nego u bolesnika liječenih samo metotreksatom tijekom 6 i 12 mjeseci (vidjeti Tablicu 4).
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 6).
Radiološki nalazi u bolesnika liječenih kombinacijom lijeka Humira i metotreksata pokazali su znatno sporiju progresiju strukturnih oštećenja zglobova nego u bolesnika liječenih samo metotreksatom tijekom 6 i 12 mjeseci (vidjeti Tablicu 6).
Humira/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see Table 8).
Radiološki nalazi u bolesnika liječenih kombinacijom lijeka Humira i metotreksata pokazali su znatno sporiju progresiju strukturnih oštećenja zglobova nego u bolesnika liječenih samo metotreksatom tijekom 6 i 12 mjeseci (vidjeti Tablicu 8).
Hungary
Gödöllő 2100 Mađarska
Hungary (Headquarters: 4042 Debrecen, Pallagi út 13)
Mađarska (Administrativno sjedište: 4042 Debrecen, Pallagi út 13)
Hungary/ Magyarország
Mađarska/Magyarország
hunger
glad
hunger disease of the gallbladder
glad bolest žučnog mjehura
Hunger, Pyrexia
Glad, pireksija
Hunter syndrome is an X-linked disease caused by insufficient levels of the lysosomal enzyme iduronate-2-sulfatase.
Hunterov sindrom je X-vezana bolest koju uzrokuju nedovoljne razine lizosomskog enzima iduronat-2- sulfataze.
Huntercombe Lane South Taplow, Maidenhead Berkshire, SL6 0PH-UK United Kingdom
Huntercombe Lane South Taplow, Maidenhead Berkshire, SL6 0PH-UK Velika Britanija
HVL (>600,000
17,8; 26,0
HVL (>600,000
48,6; 62,0
Hvězdova 1716/2b, 140 78 Praha 4 Czech Republic
Hvězdova 1716/2b, 140 78 Praha 4 Republika Češka
Hvězdova 1716/2b, 140 78 Praha 4 Czech Republic
Hvězdova 1716/2b, 140 78 Praha 4 Češka Republika
Hycamtin 0.25 mg capsules are white to yellowish white and imprinted with ‘Hycamtin’ and ‘0.25 mg’.
Hycamtin 0,25 mg kapsule su bijele do žućkasto bijele, s oznakom «Hycamtin» i «0,25mg».
Hycamtin 1 mg capsules are pink and imprinted with ‘Hycamtin’ and ‘1 mg’.
Hycamtin 1 mg kapsule su ružičaste, s oznakom «Hycamtin» i «1 mg».
HYCAMTIN 1 mg is available in cartons containing 1 vial and 5 vials.
HYCAMTIN 1 mg je dostupan u kutijama od 1 bočice i 5 bočica.
HYCAMTIN 1 mg is supplied in 5 ml type I flint glass vials, together with 13 mm grey butyl rubber stoppers and 13 mm aluminium seals with plastic flip-off caps.
HYCAMTIN 1 mg je pakiran u bočice od kremenog stakla tipa I, volumena 5 ml, zatvorene sivim gumenim čepom (butil guma) od 13 mm i aluminijskim pokrovom od 13 mm te pokrivene plastičnom flip off kapicom.
HYCAMTIN 1 mg vials must be reconstituted with 1.1 ml water for injections.
Bočice lijeka Hycamtin 1 mg moraju se rekonstituirati s 1,1 ml sterilne vode za injekcije.
HYCAMTIN 4 mg is available in cartons containing 1 vial and 5 vials.
HYCAMTIN 4 mg je dostupan u kutijama od 1 bočice i 5 bočica.
HYCAMTIN 4 mg is supplied in 17 ml type I flint glass vials, together with 20 mm grey butyl rubber stoppers and 20 mm aluminium seals with plastic flip-off caps.
HYCAMTIN 4 mg je pakiran u bočice od kremenog stakla tipa I, volumena 17 ml, zatvorene sivim gumenim čepom (butil guma) od 20 mm i aluminijskim pokrovom od 20 mm te pokrivene plastičnom flip off kapicom.
HYCAMTIN 4 mg vials must be reconstituted with 4 ml water for injections.
Bočice lijeka Hycamtin 4 mg moraju se rekonstituirati s 4 ml sterilne vode za injekcije.
Hycamtin can make people feel tired.
Hycamtin izaziva osjećaj umora.
HYCAMTIN capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
HYCAMTIN kapsule su indicirane u monoterapiji odraslih bolesnika s recidivom karcinoma pluća malih stanica SCLC (od eng. small cell lung cancer) koji nisu pogodni za ponovno uvođenje prve linije terapije (vidjeti dio 5.1).
Hycamtin capsules may be taken with or without food.
Hycamtin kapsule mogu se uzeti s ili bez jela.
HYCAMTIN capsules should not be opened or crushed.
HYCAMTIN kapsule ne smiju se otvarati niti drobiti.
Hycamtin comes as a powder for concentrate for solution for intravenous infusion.
Hycamtin je prašak za koncentrat za otopinu za infuziju u venu.
Hycamtin helps to destroy tumours.
Hycamtin pomaže u uništavanju tumora.
Hycamtin is available in packs containing 10 capsules of 0.25 mg or 1 mg topotecan.
Hycamtin je dostupan u pakiranju koje sadrži 10 kapsula od 0,25 mg ili 1 mg topotekana.
HYCAMTIN is contraindicated in patients who
HYCAMTIN je kontraindiciran u:
HYCAMTIN is contraindicated in patients who
Primjena lijeka Hycamtin je kontraindicirana u:
Hycamtin is used to treat:
Hycamtin se koristi u liječenju:
Hycamtin may harm a baby conceived before, during or soon after treatment.
Hycamtin može naškoditi djetetu koje je začeto prije, za vrijeme ili ubrzo nakon liječenja.
Hycamtin with food and drink
Hycamtin s hranom i pićem
hydrobromide
bromid
Hydrochloric acid
hidroklorna kiselina
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Purified water.
Hidroklorna kiselina (za prilagođavanje pH) Natrijev hidroksid (za prilagođavanje pH) Pročišćena voda.
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
cinkov acetat kloridna kiselina (za podešavanje pH) natrijev hidroksid (za podešavanje pH) voda za injekcije
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
Kloridna kiselina (za podešavanje pH) Natrijev hidroksid (za podešavanje pH) Voda za injekcije
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections
Kloridna kiselina (za prilagodbu pH) Natrijev hidroksid (za prilagodbu pH) Voda za injekcije
Hydrochloric acid (for pH-adjustment)
kloridna kiselina (za podešavanje pH)
Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment)
Kloridna kiselina (za podešavanje pH) Natrijev hidroksid (za podešavanje pH)
Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment)
voda za injekcije kloridna kiselina (za podešavanje pH) natrijev hidroksid (za podešavanje pH)
Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment) Water for injections
Kloridna kiselina (za podešavanje pH) Natrijev hidroksid (za podešavanje pH) Voda za injekcije
Hydrochloric acid (to adjust pH) Sodium hydroxide (to adjust pH)
Kloridna kiselina (za podešavanje pH) Natrijev hidroksid (za podešavanje pH)
Hydrochloric acid 0.1 N. Water for injections.
kloridna kiselina 0,1 M. voda za injekcije.
Hydrochloric acid 30 % Water for injections
30 % kloridna kiselina voda za injekcije
Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0 – 7.8.
Kloridna kiselina i natrijev hidroksid mogu se koristiti za podešavanje pH na 7,0 - 7,8.
Hydrochloric acid and sodium hydroxide may be used to adjust pH to 7.0-7.8.
Kloridna kiselina i natrijev hidroksid mogu se koristiti za podešavanje pH na 7,0 - 7,8.
Hydrochloric acid and sodium hydroxide maybe used to adjust pH to 7.0 – 7.8.
Kloridna kiselina i natrijev hidroksid mogu se koristiti za podešavanje pH na 7,0 - 7,8.
Hydrochloric acid and/or sodium hydroxide (to adjust pH) Purified water
natrijev klorid tiloksapol kloridna kiselina i/ili natrijev hidroksid (za podešavanje pH vrijednosti) pročišćena voda
Hydrochloric acid concentrated (for pH adjustment)
kloridna kiselina, koncentrirana (za podešavanje pH)
Hydrochloric acid Water for injections
Kloridna kiselina Voda za injekcije
Hydrochloric acid, concentrated
hidroklorna kiselina
Hydrochloric acid, concentrated
hidroklorna kiselina, koncentrirana
hydrochloric acid, sodium hydroxide.
kloridnu kiselinu, natrijev hidroksid.
Hydrochloric acid5
klorovodična kiselina5
hydrochloride/Efavirenz
atovakvon:
hydrochloride/Efavirenz
varfarin/efavirenz acenokumarol/efavirenz
hydrochlorothiazide (or any combination with hydrochlorothiazide)
hidroklorotiazid (ili bilo koja kombinacija s hidroklorotiazidom)
hydrochlorothiazide (or any combination with hydrochlorothiazide)
hidroklorotiazida (ili bilo koja kombinacija s hidroklorotiazidom)
hydrochlorothiazide (or any combination with hydrochlorothiazide)
hidroklorotiazida (ili bilo koje kombinacije s hidroklorotiazidom)
Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase leading to a lowering of your blood pressure.
Hidroklorotiazid pripada skupini lijekova koji se nazivaju tiazidski diuretici, koji uzrokuju povećano izlučivanje urina, što također snižava krvni tlak.
Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure.
Hidroklorotiazid pripada skupini lijekova koji se nazivaju tiazidski diuretici, koji uzrokuju povećano izlučivanje urina, što također dovodi do snižavanja Vašeg krvnog tlaka.
Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure.
Hidroklorotiazid pripada skupini lijekova koji se nazivaju tiazidski diuretici, koji uzrokuju povećano izlučivanje urina, što također snižava krvni tlak.
Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.
Hidroklorotiazid u sastavu lijeka može dovesti do pozitivnog analitičkog rezultata antidoping testa.
Hydrochlorothiazide crosses the placental but not the blood-brain barrier, and is excreted in breast milk.
Hidroklorotiazid prolazi placentalnu, ali ne i krvno- moždanu barijeru te se izlučuje u majčino mlijeko.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 1/kg.
Hidroklorotiazid se 68 % veže na proteine u plazmi, a njegov prividni volumen distribucije je 0,83- 1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 1/kg.
Hidroklorotiazid se 68% veže na proteine u plazmi, a njegov prividni volumen distribucije je 0,83- 1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 l/kg.
Hidroklorotiazid se 68 % veže na proteine u plazmi, a njegov prividni volumen distribucije je 0,83- 1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 l/kg.
Hidroklorotiazid se 68% veže na proteine u plazmi, a njegov prividni volumen distribucije je 0,83 – 1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 l/kg.
Hidroklorotiazid se 68% veže na proteine u plazmi, a njegov prividni volumen distribucije je 0,83- 1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83-1.14 l/kg.
Hidroklorotiazid se 68% veže na proteine u plazmi, a njegov prividni volumen distribucije je 0,83- 1,14 l/kg.
Hydrochlorothiazide is 68 % protein- bound in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg.
Za proteine u plazmi veže se 68% hidroklorotiazida, a njegov prividni volumen distribucije iznosi 0,83-1,14 l/kg.
Hydrochlorothiazide is 68% protein- bound in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg.
Za proteine u plazmi veže se 68% hidroklorotiazida, a njegov prividni volumen distribucije iznosi 0,83-1,14 l/kg.
Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.
Hidroklorotiazid se ne smije primjenjivati u gestacijskom edemu, gestacijskoj hipertenziji, ili preeklampsiji zbog rizika od smanjenog violumena plazme i hipoperfuzije placente, bez korisnog učinka na tijek bolesti.
Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.
Hidroklorotiazid: iako su iz nekih eksperimentalnih modela proizašli dvosmisleni dokazi o genotoksičnom i karcinogenom učinku, ekstenzivno iskustvo s primjenom u ljudi nije pokazalo vezu između primjene hidroklorotiazida i porasta pojave neoplazmi.
Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.
Hidroklorotiazid: iako su iz nekih eksperimentalnih modela proizašli dvosmisleni dokazi o genotoksičnom i karcinogenom učinku, ekstenzivno iskustvo s primjenom u ljudi nije pokazalo vezu između primjene hidroklorotiazida i porasta pojave novotvorina.
Hydrochlorothiazide: Following oral administration of Kinzalkomb peak concentrations of hydrochlorothiazide are reached in approximately 1.0 – 3.0 hours after dosing.
Hidroklorotiazid: Nakon peroralne primjene Kinzalkomba, vršne koncentracije hidroklorotiazida postižu se za oko 1,0-3,0 sati nakon doziranja.
Hydrochlorothiazide: Following oral administration of MicardisPlus peak concentrations of hydrochlorothiazide are reached in approximately 1.0 – 3.0 hours after dosing.
Hidroklorotiazid: Nakon peroralne primjene MicardisPlusa, vršne koncetracije hidroklorotiazida postižu se za oko 1,0-3,0 sati nakon doziranja.
Hydrochlorothiazide: Following oral administration of PritorPlus peak concentrations of hydrochlorothiazide are reached in approximately 1.0 – 3.0 hours after dosing.
Hidroklorotiazid: Nakon peroralne primjene PritorPlusa, vršne koncentracije hidroklorotiazida postižu se za oko 1,0-3,0 sati nakon doziranja.
Hydrochlorothiazide: Following oral administration of PritorPlus peak concentrations of hydrochlorothiazide are reached in approximately 1.0 – 3.0 hours after dosing.
Hidroklorotiazid: Nakon peroralne primjene PritorPlusa, vršne koncetracije hidroklorotiazida postižu se za oko 1,0-3,0 sati nakon doziranja.
Hydrochlorothiazide: Following oral administration of Tolucombi peak concentrations of hydrochlorothiazide are reached in approximately 1.0 – 3.0 hours after dosing.
Hidroklorotiazid: nakon peroralne primjene lijeka Tolucombi, vršne koncetracije hidroklorotiazida postižu se za oko 1,0-3,0 sati nakon doziranja.
Hydrochlorothirazide:
Hidroklorotiazid:
Hydrocodone
pojedinačna
hydrocodone dose by 50%
manjenje doze
hydrocodone/
kombinacija
hydrocodone/ paracetamol)
kao fiksna
Hydrocortisone aceponate 0.584 mg/ml.
Hidrokortizon aceponat 0,584 mg/ml
Hydrocortisone aceponate 0.584 mg/ml.
Hidrokortizon aceponat 0.584 mg/ml
Hydrocortisone aceponate 1.11 mg/ml
Hidrokortizon aceponat 1,11 mg/ ml
Hydrocortisone aceponate 1.11 mg/ml, Miconazole as nitrate 15.1 mg/ml, Gentamicin as sulphate 1,505 IU/ml.
Gentamicin (u obliku sulfata) 1505 IJ/ ml
Hydrocortisone aceponate administered topically accumulates and is metabolised in skin, as suggested by radioactivity distribution studies and pharmacokinetic data.
Lokalno nanesen hidrokortizon aceponat se akumulira i metabolizira u koži što je nagoviješteno u ispitivanjima distribucije radioaktivno obilježene tvari farmakokinetičkim podacima.
Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.
Nanošenje hidrokortizon aceponata na oštećenja kože omogućava brzo umanjenje crvenila, nadražaja i češanja dok su opći efekti minimalni.
Hydrocortisone aceponate belongs to the diesters’ class of glucocorticosteroids.
Hidrokortizon aceponat spada u diesterske glukokortikoide.
Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis.
Hidokortizon aceponat (HCA) je dermokortikoid sa jakom intrinzičnom glukokortikoidnom aktivnošću što znači olakšanje upalnih procesa i svrbeža i vodi ka brzom poboljšanju lezija na koži koje se opažaju kod upalnih i pruritičnih dermatoza.
Hydrocortisone aceponate thus accumulates in the dog’s skin allowing local efficacy at low dosage.
HCA se stoga akumulira u kožu psa što omogućava lokalnu djelotvornost u manjim dozama.
hydrocortisone and prednisolone (corticosteroids) used to treat diseases that involve inflammation like asthma and arthritis
hidrokortizon ili prednizolon (kortikosteroidi) koji se koriste za liječenje upalnih bolesti poput astme i artritisa
Hydrocortisone is a glucocorticoid and the synthetic form of endogenously produced cortisol.
Hidrokortizon je glukokortikoid i sintetički oblik endogeno proizvedenog kortizola.
Hydrocortisone is eliminated completely by metabolism by 11ßHSD type 1 and type 2 enzymes and CYP 3A4 in the liver and in peripheral tissue.
Hidrokortizon se potpuno eliminira metabolički putem enzima 11ßHSD tip 1 i tip 2 i enzima CYP 3A4 u jetri i perifernom tkivu.
Hydrolysed gelatin Sodium chloride
hidrolizirana želatina natrijev klorid
Hydrolysed gelatin Sodium chloride Sorbitol
hidrolizirana želatina natrijev klorid sorbitol
hydrolytic glass vials type I (EP) with butyl stopper (EP) and aluminium seal
Hidrolitična staklena bočica tipa I (EP) s butil čepom (EP) i aluminijskim pečatom
hydrolytic glass vials type II (EP) with butyl stopper (EP) and aluminium seal
Hidrolitična staklena bočica tipa I (EP) s butil čepom (EP) i aluminijskim pečatom
Hydromorphone hydrochloride
hidromorfonklorid
Hydronephrosis Renal failure Urine abnormality
hidronefroza, zatajenje bubrega, nenormalna mokraća
Hydronephrosis,
labost
Hydronephrosis, Urinary incontinence, Haematuria, Nocturia, Blood creatinine increased
hidronefroza, urinarna inkontinencija, hematurija, noćno mokrenje, porast vrijednosti kreatinina u krvi
hydroxide and 1.8 grams
(ekvivalent 3,6 g aluminij
hydroxide and 1.8 grams
hidroksida i 1,8 g magnezij
hydroxide antacids nor famotidine
aluminijev/magnezijev hidroksid kao
hydroxide-simethicone
hidroksid-simetikon
hydroxide; calcium
kalcijev karbonat
Hydroxocobalamin
Hidroksokobalamin
Hydroxy Methyl Glutaryl Coenzyme A (HMG CoA) reductase inhibitors
Inhibitori hidroksimetilglutaril koenzim A (HMG KoA) reduktaze
Hydroxy methyl glutaryl coenzyme A reductase inhibitors
Inhibitori hidroksimetilglutaril koenzim A reduktaze